MATTESINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.537
EU - Europa 567
AS - Asia 214
AF - Africa 5
SA - Sud America 4
OC - Oceania 1
Totale 2.328
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.533
IE - Irlanda 150
SE - Svezia 131
RU - Federazione Russa 117
CN - Cina 74
IT - Italia 64
HK - Hong Kong 59
PL - Polonia 52
SG - Singapore 35
ES - Italia 18
VN - Vietnam 18
JO - Giordania 14
UA - Ucraina 12
DE - Germania 10
IR - Iran 7
GB - Regno Unito 5
CA - Canada 4
KE - Kenya 4
JP - Giappone 3
AR - Argentina 2
BR - Brasile 2
FI - Finlandia 2
FR - Francia 2
PK - Pakistan 2
RS - Serbia 2
GR - Grecia 1
KR - Corea 1
MU - Mauritius 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PH - Filippine 1
Totale 2.328
Salva come PNG Salva come JPEG
Città #
Fairfield 313
Seattle 144
Dublin 138
Woodbridge 136
Houston 123
Ashburn 116
Cambridge 112
Wilmington 89
Medford 58
Lawrence 55
Warsaw 52
Princeton 46
Buffalo 44
Chandler 34
Beijing 32
Moscow 28
Hong Kong 26
Ann Arbor 24
Altamura 22
Singapore 19
Barcelona 18
Dong Ket 16
San Diego 16
Shanghai 15
Norwalk 12
Kent 11
Falls Church 10
Florence 10
Hillsboro 8
Tehran 6
Andover 5
Boardman 5
Nairobi 4
New York 4
Redmond 4
Toronto 4
Guangzhou 3
Laurel 3
Lucera 3
Rome 3
Abbiategrasso 2
Belgrade 2
Boston 2
Buenos Aires 2
Fuzhou 2
Helsinki 2
London 2
Milan 2
Mykolayiv 2
Recife 2
Redwood City 2
Tyumen 2
Zhuhai 2
Ardabil 1
Auckland 1
Bologna 1
Casoria 1
Cedar Knolls 1
Foshan 1
Genoa 1
Haining 1
Hounslow 1
Los Angeles 1
Menlo Park 1
Prato 1
Prescot 1
Santa Clara 1
Sesto San Giovanni 1
Thessaloniki 1
Torino 1
University Center 1
Wuhan 1
Wuhu 1
Ysselsteyn 1
Totale 1.818
Salva come PNG Salva come JPEG
Nome #
The DESolve novolimus bioresorbable Scaffold: From bench to bedside 109
Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: Insights from the GHOST-EU registry 83
Bioabsorbable vascular scaffold overexpansion: Insights from in vitro post-expansion experiments 77
Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: A European perspective 76
A Brief History of Coronary Artery Stents 72
Biodegradable vascular scaffold: is optimal expansion the key to minimising flow disturbances and risk of adverse events? 72
Results of comprehensive cardiovascular diagnostic work-up in HIV positive patients 70
Bioresorbable vascular scaffold radial expansion and conformation compared to a metallic platform: Insights from in vitro expansion in a coronary artery lesion model 64
Absorb bioresorbable vascular scaffold: What have we learned after 5 years of clinical experience? 62
Optical coherence tomography guidance for percutaneous coronary intervention with bioresorbable scaffolds 61
Absorb vs. DESolve: An optical coherence tomography comparison of acute mechanical performances 61
A simple step-by-step approach for proficient utilization of the EchoNavigator technology for left atrial appendage occlusion 59
Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study) 57
Calcium: A predictor of interventional treatment failure across all fields of cardiovascular medicine 57
Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry 56
Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry 56
Indications and immediate and long-term results of a novel pericardium covered stent graft: Consecutive 5 year single center experience 55
Impact of stent strut design in metallic stents and biodegradable scaffolds 54
Percutaneous Trans-septal Mitral Valve-in-Ring Implantation Using a Transcatheter Balloon-Expandable Transcatheter Heart Valve With Elective Intra-Procedural Artero-Venous ECMO in a Patient With Severely Reduced Left Ventricular Ejection Fraction 54
An amber signal lights up before the red: Do not dismiss it 53
Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: Development and internal validation of the PSP score 53
Very high-pressure dilatation for undilatable coronary lesions: Indications and results with a new dedicated balloon 52
Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry 52
Optical coherence tomography characteristics of in-stent restenosis are different between first and second generation drug eluting stents 52
The Forgotten Art of Balloon Angioplasty 49
1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents A Propensity-Matched Comparison of the GHOST-EU and XIENCE v USA Registries 49
Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions 49
Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation 49
Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry 48
Will Optical Coherence Tomography Become the Standard Imaging Tool for Percutaneous Coronary Intervention Guidance? 47
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry 47
Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty 45
TAVR in patients with hip fracture and severe aortic stenosis: how and when? 43
Percutaneous Watchman FLX implantation in a patient with previous mitral valve surgery and large-sized left atrial appendage 42
Il trattamento delle occlusioni coronariche croniche: Stato dell'arte 40
Patent foramen ovale closure: how to choose the right device for the right patient 37
[Tips and tricks for using extracorporeal life support devices in the intensive cardiac care unit] 37
Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry 33
ABSORB biodegradable stents versus second-generation metal stents: A comparison study of 100 complex lesions treated under OCT guidance 33
EuroCTO Club 2018 meeting: "Experts Live" in Toulouse 32
Riserva frazionale di flusso: una breve guida pratica all'utilizzo per l'interventista e il punto di vista del cardiologo clinico 31
Stop adding metal layers: Will bioabsorbable scaffolds become the gold standard for late in-stent restenosis and neo-atherosclerosis? 29
A Sex-Based Analysis From the RAIN-CARDIOGROUP VII Study (VeRy Thin Stents for Patients With Left MAIn or BifurcatioN in Real Life) on Left Main Stenting 28
No-Reflow Complicating Chronic Total Occlusion Coronary Revascularization 27
Bioresorbable Scaffold Thrombosis: Why BRS Size Matters 26
Inducing persistent flow disturbances accelerates atherogenesis and promotes thin cap fibroatheroma development in D374Y-PCSK9 hypercholesterolemic minipigs 23
Urgent coronary angiography in out-of-hospital cardiac arrest: a retrospective single centre investigation 14
Peripheral intravascular lithotripsy for transcatheter aortic valve implantation: a multicentre observational study 8
Totale 2.383
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.893
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.893
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020457 0 21 15 40 58 63 65 60 60 35 27 13
2020/2021345 16 22 12 38 53 49 10 24 36 38 19 28
2021/2022334 5 14 19 25 11 20 9 25 16 11 58 121
2022/2023507 78 114 42 16 2 92 74 21 44 2 18 4
2023/2024247 11 30 51 22 17 16 8 37 10 17 19 9
2024/2025153 102 51 0 0 0 0 0 0 0 0 0 0
Totale 2.383